title: A comparative study on the return to ovulation following chronic use of once-a-month injectable contraceptives.
abstract: A comparative study was undertaken involving 21 Mexican women who discontinued the use of medroxyprogesterone acetate 25 mg plus oestradiol cypionate 5 mg (Cyclofem) and norethisterone enanthate 50 mg plus oestradiol valerate 5 mg (Mesigyna) to assess the time required for the return to menses and ovulation. All subjects were exposed to once-a-month injectable contraceptives for two years and were followed for 120 days after the last injection. The urinary concentration of oestrone glucuronide and pregnanediol glucuronide was determined daily in all subjects beginning one month after the last injection. The results disclosed that ovulatory cycles were documented after 120 days of the last injection in six women of each studied group. Similar endometrial bleeding patterns were observed in both groups, indicating that the two drugs have alike pharmacokinetic and pharmacodynamic effects.
authors.affiliation: Department of Reproductive Biology, Medicine School of Torreon, University of Coahuila, Mexico.
authors.forename: S
authors.initials: S
authors.lastname: Bassol
authors.forename: C
authors.initials: C
authors.lastname: Hernandez
authors.forename: M P
authors.initials: MP
authors.lastname: Nava
authors.forename: A M
authors.initials: AM
authors.lastname: Trujillo
authors.forename: D
authors.initials: D
authors.lastname: Luz de la Cruz
mesh_terms: D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D004338:Drug Combinations; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004970:Estrone / Q000652:urine; D005260:Female; D005965:Glucuronates / Q000652:urine; D006801:Humans; D007273:Injections, Intramuscular; D007700:Kinetics; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008800:Mexico; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D010060:Ovulation / Q000502:physiology*; D011276:Pregnanediol / Q000652:urine
chemical_list: D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D005965:Glucuronates; C418365:estradiol, norethindrone drug combination; D004970:Estrone; D004958:Estradiol; C034528:CycloProvera; D017258:Medroxyprogesterone Acetate; D011276:Pregnanediol; D009640:Norethindrone